229 related articles for article (PubMed ID: 16684433)
1. Efficacy and safety of tamsulosin for benign prostatic hyperplasia: clinical experience in the primary care setting.
Flannery MT; Ramsdell J; Ranhosky A; Davidai G; Ruoff G
Curr Med Res Opin; 2006 Apr; 22(4):721-30. PubMed ID: 16684433
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of tamsulosin hydrochloride compared to doxazosin in the treatment of Indonesian patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
Rahardjo D; Soebadi DM; Sugandi S; Birowo P; Djati W; Wahyudi I
Int J Urol; 2006 Nov; 13(11):1405-9. PubMed ID: 17083392
[TBL] [Abstract][Full Text] [Related]
3. The effect of alpha-blocker and 5alpha-reductase inhibitor intake on sexual health in men with lower urinary tract symptoms.
Barqawi AB; Myers JB; O'Donnell C; Crawford ED
BJU Int; 2007 Oct; 100(4):853-7. PubMed ID: 17662074
[TBL] [Abstract][Full Text] [Related]
4. Clinical comparison of selective and non-selective alpha 1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: studies on tamsulosin and terazosin in Chinese patients. The Chinese Tamsulosin Study Group.
Na YJ; Guo YL; Gu FL
J Med; 1998; 29(5-6):289-304. PubMed ID: 10503165
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia.
Nordling J
BJU Int; 2005 May; 95(7):1006-12. PubMed ID: 15839922
[TBL] [Abstract][Full Text] [Related]
6. Clinical impact of tamsulosin on generic and symptom-specific quality of life for benign prostatic hyperplasia patients: using international prostate symptom score and Rand Medical Outcomes Study 36-item Health Survey.
Suzuki H; Yano M; Awa Y; Nakatsu H; Egoshi K; Mikami K; Ota S; Okano T; Hamano S; Ohki T; Furuya Y; Ichikawa T
Int J Urol; 2006 Sep; 13(9):1202-6. PubMed ID: 16984553
[TBL] [Abstract][Full Text] [Related]
7. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study.
Nishino Y; Masue T; Miwa K; Takahashi Y; Ishihara S; Deguchi T
BJU Int; 2006 Apr; 97(4):747-51, discussion 751. PubMed ID: 16536766
[TBL] [Abstract][Full Text] [Related]
8. Long-term study to assess the efficacy of tamsulosin in the control of symptoms and complications developed in patients with symptomatic benign prostatic hyperplasia (OMNICONTROL study): first-year follow-up report.
Palacio A; Hernández C; Marqués A; Prats J; Espinosa FJ
Arch Esp Urol; 2004 May; 57(4):451-60. PubMed ID: 15270291
[TBL] [Abstract][Full Text] [Related]
9. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study.
Roehrborn CG; Siami P; Barkin J; Damião R; Becher E; Miñana B; Mirone V; Castro R; Wilson T; Montorsi F;
Eur Urol; 2009 Feb; 55(2):461-71. PubMed ID: 19013011
[TBL] [Abstract][Full Text] [Related]
10. Long-term treatment outcome of tamsulosin for benign prostatic hyperplasia.
Ichioka K; Ohara H; Terada N; Matsui Y; Yoshimura K; Terai A; Arai Y
Int J Urol; 2004 Oct; 11(10):870-5. PubMed ID: 15479292
[TBL] [Abstract][Full Text] [Related]
11. Long-term, open-label, phase III multicenter study of tamsulosin in benign prostatic hyperplasia.
Narayan P; Lepor H
Urology; 2001 Mar; 57(3):466-70. PubMed ID: 11248621
[TBL] [Abstract][Full Text] [Related]
12. Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice.
Vallancien G; Emberton M; Alcaraz A; Matzkin H; van Moorselaar RJ; Hartung R; Harving N; Elhilali M;
BJU Int; 2008 Apr; 101(7):847-52. PubMed ID: 18321317
[TBL] [Abstract][Full Text] [Related]
13. Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled trial.
Gotoh M; Kamihira O; Kinukawa T; Ono Y; Ohshima S; Origasa H;
BJU Int; 2005 Sep; 96(4):581-6. PubMed ID: 16104914
[TBL] [Abstract][Full Text] [Related]
14. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study.
Roehrborn CG; Siami P; Barkin J; Damião R; Major-Walker K; Morrill B; Montorsi F;
J Urol; 2008 Feb; 179(2):616-21; discussion 621. PubMed ID: 18082216
[TBL] [Abstract][Full Text] [Related]
15. Tamsulosin: effect on quality of life in 2740 patients with lower urinary tract symptoms managed in real-life practice in Spain.
Batista JE; Palacio A; Torrubia R; Hernández C; Vicente J; Resel L;
Arch Esp Urol; 2002; 55(1):97-105. PubMed ID: 11957763
[TBL] [Abstract][Full Text] [Related]
16. Terazosin in the treatment of hypertension and symptomatic benign prostatic hyperplasia: a primary care trial.
Guthrie R
J Fam Pract; 1994 Aug; 39(2):129-33. PubMed ID: 7520053
[TBL] [Abstract][Full Text] [Related]
17. Tamsulosin 0.4 mg once daily: tolerability in older and younger patients with lower urinary tract symptoms suggestive of benign prostatic obstruction (symptomatic BPH). The European Tamsulosin Study Group.
Chapple CR; Baert L; Thind P; Höfner K; Khoe GS; Spångberg A
Eur Urol; 1997; 32(4):462-70. PubMed ID: 9412807
[TBL] [Abstract][Full Text] [Related]
18. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group.
Lepor H
Urology; 1998 Jun; 51(6):892-900. PubMed ID: 9609623
[TBL] [Abstract][Full Text] [Related]
19. Doxazosin gastrointestinal therapeutic system versus tamsulosin for the treatment of benign prostatic hyperplasia: a study in Chinese patients.
Xue Z; Zhang Y; Ding Q; He Z; Wang J; Xu K
Int J Urol; 2007 Feb; 14(2):118-22. PubMed ID: 17302567
[TBL] [Abstract][Full Text] [Related]
20. Long-term use of tamsulosin to treat lower urinary tract symptoms/benign prostatic hyperplasia.
Schulman CC; Lock TM; Buzelin JM; Boeminghaus F; Stephenson TP; Talja M;
J Urol; 2001 Oct; 166(4):1358-63. PubMed ID: 11547074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
